Generic Miudella Availability
Last updated on Apr 10, 2025.
Miudella is a brand name of copper topical, approved by the FDA in the following formulation(s):
MIUDELLA (copper - system;intrauterine)
-
Manufacturer: SEBELA WOMENS HLTH
Approval date: February 24, 2025
Strength(s): N/A [RLD]
Is there a generic version of Miudella available?
No. There is currently no therapeutically equivalent version of Miudella available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Miudella. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Intrauterine device with retrieval thread
Patent 10,022,264
Issued: July 17, 2018
Inventor(s): Tal; Michael et al.
Assignee(s): CONTRAMED, LLC (Campbell, CA)An intrauterine contraceptive system may include a contraceptive intrauterine device, a retrieval thread permanently attached to the intrauterine device and an insertion device for inserting the intrauterine device into a uterus. The system may also include a release thread releasably coupled with the intrauterine device. The intrauterine device may be deployable out of a distal end of the insertion device and may be configured to change from a delivery configuration when housed in the insertion device to a deployed configuration when deployed in a uterus. The retrieval thread and the optional release thread may be at least partially housed within the insertion device during insertion of the intrauterine device into the uterus. The release thread may extend from the intrauterine device through the insertion device to an attachment point at or near a proximal end of the insertion device.
Patent expiration dates:
- March 22, 2034✓
- March 22, 2034
-
Intrauterine contraceptive device
Patent 10,159,596
Issued: December 25, 2018
Inventor(s): Tal; Michael et al.
Assignee(s): SEBELA VLC LIMITED (Hamilton, BM)A method for promoting contraception by placing a contraceptive device within a uterus without blocking fallopian tubes may involve advancing a distal end of a delivery device through a cervix, advancing the contraceptive device comprising an elongate shape memory member out of the distal end of the delivery device and into the uterus, and limiting inferior migration of the contraceptive device within the uterus. Inferior migration may be limited by allowing the contraceptive device to assume a shape, when subjected to pressure that tends to cause a downward migration of the device within the uterus, in which an expandable middle portion of the device is expanded to contact the inner wall of the uterus and thus limit the downward migration of the device.
Patent expiration dates:
- August 14, 2032✓
- August 14, 2032
-
Intrauterine contraceptive device
Patent 10,166,141
Issued: January 1, 2019
Inventor(s): Tal; Michael et al.
Assignee(s): SEBELA VLC LIMITED (Hamilton, BM)A method for promoting contraception by placing a contraceptive device within a uterus without blocking fallopian tubes may involve advancing a distal end of a delivery device through a cervix, advancing the contraceptive device comprising an elongate shape memory member out of the distal end of the delivery device and into the uterus, and limiting inferior migration of the contraceptive device within the uterus. Inferior migration may be limited by allowing the contraceptive device to assume a shape, when subjected to pressure that tends to cause a downward migration of the device within the uterus, in which an expandable middle portion of the device is expanded to contact the inner wall of the uterus and thus limit the downward migration of the device.
Patent expiration dates:
- June 13, 2034✓
- June 13, 2034
-
Intrauterine device with controlled copper ion elution
Patent 10,188,546
Issued: January 29, 2019
Inventor(s): Tal; Michael et al.
Assignee(s): SEBELA VLC LIMITED (Hamilton, BM)An intrauterine contraceptive device may include a frame made completely or partially of a first metal having a first galvanic potential and at least one metallic member coupled with the frame that is made of a second metal having a second galvanic potential different from the first galvanic potential. In some embodiments, the first galvanic potential may be more anodic than the second galvanic potential. In alternative embodiments, the first galvanic potential may be more cathodic than the second galvanic potential. In one embodiment, the first metal is Nitinol, and the second metal is copper. In some embodiments, the first and second galvanic potentials may be configured to achieve, at least approximately, a desired copper ion elution rate for the intrauterine device.
Patent expiration dates:
- August 14, 2032✓
- August 14, 2032
-
Intrauterine device with retrieval thread
Patent 10,398,588
Issued: September 3, 2019
Inventor(s): Tal; Michael et al.
Assignee(s): SEBELA VLC LIMITED (Hamilton, BM)An intrauterine contraceptive system may include a contraceptive intrauterine device, a retrieval thread permanently attached to the intrauterine device and an insertion device for inserting the intrauterine device into a uterus. The system may also include a release thread releasably coupled with the intrauterine device. The intrauterine device may be deployable out of a distal end of the insertion device and may be configured to change from a delivery configuration when housed in the insertion device to a deployed configuration when deployed in a uterus. The retrieval thread and the optional release thread may be at least partially housed within the insertion device during insertion of the intrauterine device into the uterus. The release thread may extend from the intrauterine device through the insertion device to an attachment point at or near a proximal end of the insertion device.
Patent expiration dates:
- February 24, 2034✓✓
- February 24, 2034
-
Intrauterine device with controlled copper ion elution
Patent 10,918,516
Issued: February 16, 2021
Inventor(s): Tal; Michael et al.
Assignee(s): SEBELA VLC LIMITED (Hamilton, BM)A method of manufacturing an intrauterine device (IUD) for contraception that has a desired copper elution rate is described. The method may involve selecting an elongate shape memory member comprising a first metal having a first galvanic potential, selecting at least one attachment member comprising a second metal having a second galvanic potential that is different from the first galvanic potential, attaching the attachment member(s) to the shape memory member, and shaping the shape memory member to form a frame of the intrauterine contraceptive device. The first metal and the second metal are specifically selected as materials for the shape memory member and the attachment member(s), in order to achieve the desired copper elution rate.
Patent expiration dates:
- January 23, 2037✓
- January 23, 2037
-
Intrauterine device with retrieval thread
Patent 11,207,209
Issued: December 28, 2021
Inventor(s): Tal; Michael et al.
Assignee(s): Sebela VLC Limited (Hamilton, BM)An intrauterine contraceptive system may include a contraceptive intrauterine device, a retrieval thread permanently attached to the intrauterine device and an insertion device for inserting the intrauterine device into a uterus. The system may also include a release thread releasably coupled with the intrauterine device. The intrauterine device may be deployable out of a distal end of the insertion device and may be configured to change from a delivery configuration when housed in the insertion device to a deployed configuration when deployed in a uterus. The retrieval thread and the optional release thread may be at least partially housed within the insertion device during insertion of the intrauterine device into the uterus. The release thread may extend from the intrauterine device through the insertion device to an attachment point at or near a proximal end of the insertion device.
Patent expiration dates:
- August 16, 2034✓
- August 16, 2034
-
Intrauterine contraceptive device
Patent 11,850,181
Issued: December 26, 2023
Inventor(s): Tal; Michael et al.
Assignee(s): SEBELA VLC LIMITED (Hamilton, BM)A method for promoting contraception by placing a contraceptive device within a uterus without blocking fallopian tubes may involve advancing a distal end of a delivery device through a cervix, advancing the contraceptive device comprising an elongate shape memory member out of the distal end of the delivery device and into the uterus, and limiting inferior migration of the contraceptive device within the uterus. Inferior migration may be limited by allowing the contraceptive device to assume a shape, when subjected to pressure that tends to cause a downward migration of the device within the uterus, in which an expandable middle portion of the device is expanded to contact the inner wall of the uterus and thus limit the downward migration of the device.
Patent expiration dates:
- August 14, 2032✓
- August 14, 2032
-
Intrauterine device with retrieval thread
Patent 12,138,199
Issued: November 12, 2024
Inventor(s): Tal; Michael et al.
Assignee(s): Sebela VLC Limited (Hamilton, BM)An intrauterine contraceptive system may include a contraceptive intrauterine device, a retrieval thread permanently attached to the intrauterine device and an insertion device for inserting the intrauterine device into a uterus. The system may also include a release thread releasably coupled with the intrauterine device. The intrauterine device may be deployable out of a distal end of the insertion device and may be configured to change from a delivery configuration when housed in the insertion device to a deployed configuration when deployed in a uterus. The retrieval thread and the optional release thread may be at least partially housed within the insertion device during insertion of the intrauterine device into the uterus. The release thread may extend from the intrauterine device through the insertion device to an attachment point at or near a proximal end of the insertion device.
Patent expiration dates:
- October 18, 2033✓
- October 18, 2033
-
Intrauterine contraceptive device
Patent 9,089,418
Issued: July 28, 2015
Inventor(s): Tal; Michael et al.
Assignee(s): CONTRAMED, LLC (San Jose, CA)A method for promoting contraception by placing a contraceptive device within a uterus without blocking fallopian tubes may involve advancing a distal end of a delivery device through a cervix, advancing the contraceptive device comprising an elongate shape memory member out of the distal end of the delivery device and into the uterus, and limiting inferior migration of the contraceptive device within the uterus. Inferior migration may be limited by allowing the contraceptive device to assume a shape, when subjected to pressure that tends to cause a downward migration of the device within the uterus, in which an expandable middle portion of the device is expanded to contact the inner wall of the uterus and thus limit the downward migration of the device.
Patent expiration dates:
- April 9, 2033✓
- April 9, 2033
-
Intrauterine contraceptive device
Patent 9,265,652
Issued: February 23, 2016
Inventor(s): Tal; Michael et al.
Assignee(s): CONTRAMED, LLC (San Jose, CA)A method for promoting contraception by placing a contraceptive device within a uterus without blocking fallopian tubes may involve advancing a distal end of a delivery device through a cervix, advancing the contraceptive device comprising an elongate shape memory member out of the distal end of the delivery device and into the uterus, and limiting inferior migration of the contraceptive device within the uterus. Inferior migration may be limited by allowing the contraceptive device to assume a shape, when subjected to pressure that tends to cause a downward migration of the device within the uterus, in which an expandable middle portion of the device is expanded to contact the inner wall of the uterus and thus limit the downward migration of the device.
Patent expiration dates:
- April 28, 2034✓
- April 28, 2034
-
Intrauterine contraceptive device
Patent 9,427,351
Issued: August 30, 2016
Inventor(s): Tal; Michael et al.
Assignee(s): CONTAMED, LLC (Los Gatos, CA)A method for promoting contraception by placing a contraceptive device within a uterus without blocking fallopian tubes may involve advancing a distal end of a delivery device through a cervix, advancing the contraceptive device comprising an elongate shape memory member out of the distal end of the delivery device and into the uterus, and limiting inferior migration of the contraceptive device within the uterus. Inferior migration may be limited by allowing the contraceptive device to assume a shape, when subjected to pressure that tends to cause a downward migration of the device within the uterus, in which an expandable middle portion of the device is expanded to contact the inner wall of the uterus and thus limit the downward migration of the device.
Patent expiration dates:
- August 14, 2032✓
- August 14, 2032
-
Intrauterine device with retrieval thread
Patent 9,610,191
Issued: April 4, 2017
Inventor(s): Tal; Michael et al.
Assignee(s): CONTRAMED, LLC (San Jose, CA)An intrauterine contraceptive system may include a contraceptive intrauterine device, a retrieval thread permanently attached to the intrauterine device and an insertion device for inserting the intrauterine device into a uterus. The system may also include a release thread releasably coupled with the intrauterine device. The intrauterine device may be deployable out of a distal end of the insertion device and may be configured to change from a delivery configuration when housed in the insertion device to a deployed configuration when deployed in a uterus. The retrieval thread and the optional release thread may be at least partially housed within the insertion device during insertion of the intrauterine device into the uterus. The release thread may extend from the intrauterine device through the insertion device to an attachment point at or near a proximal end of the insertion device.
Patent expiration dates:
- February 24, 2034✓
- February 24, 2034
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- February 24, 2028 - NEW PRODUCT
More about Miudella (copper topical)
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous vaginal agents
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.